66 results about "Osteoprotegerin" patented technology

The disclosed methods and compositions for reducing cardiovascular risk factors in mammals generally includes using genistein to modulate various inflammatory and cardiovascular risk markers including: homocysteine, C-reactive protein, fibrinogen, sex hormone-binding globulin, fasting glucose, insulin, insulin resistance, and osteoprotegerin.

Devices and methods for stimulation of the vagus nerve to modulate (e.g., reduce, suppress, etc.) bone erosion. Methods and apparatus for modulating bone erosion may modulate levels of Receptor Activator for Nuclear Factor κB Ligand (RANKL), and/or to modulate (increase, enhance, etc.) osteoprotegerin (OPG) and/or OPG/RANKL ratio. Devices may include electrical stimulation devices that may be implanted, and may be activated to apply current for a proscribed duration, followed by a period without stimulation.

The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis. Methods of treatment are described using the polypeptides in conjunction with various agents, including IL-1 inhibitors, TNF-α inhibitors, and serine protease inhibitors.

In certain preferred embodiments, the present invention provides compositions and methods for the treatment of bone conditions associated with low bone density. In preferred embodiments, the present invention provides compositions and methods for the treatment of osteoprotegerin-responsive conditions.

A novel polypeptide, osteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget's disease are also provided.

The present invention relates to novel osteoprotegerin variant proteins (OVPs) that demonstrate reduce binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these OVPs are also provided. Recombinant vectors and host cells expressing these OVPs are also encompassed as are methods of producing recombinant OVPs. The present invention also relates to compositions comprising these OVPs, and to methods of treating bone diseases characterised by increased bone turnover and/or loss. The OVPs of the invention are useful for preventing bone resorption and may be used to treat any condition resulting in abnormal bone turnover or bone loss such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like.

The invention relates to the use of osteoprotegerin for treatment and/or prevention of fibrotic diseases, in particular of scleroderma.

The present invention relates to applications of a bionic silicon-calcium hybrid collagen scaffold material within fiber, specifically to the osteoclastogenesis inhibition application of the bionic silicon-calcium hybrid collagen scaffold material within fiber, and the application of the bionic silicon-calcium hybrid collagen scaffold material within fiber as the bone defect repair material. According to the present invention, calcium ions and silicic acid released by the bionic silicon-calcium hybrid collagen scaffold material within fiber under the body fluid environment can promote osteogenic differentiation of the mesenchymal stem cells and induce the mesenchymal stem cells to secrete a large number of osteoprotegerin so as to provide effects of osteoclast activation inhibiting and bone damage function inhibiting, and in the late stage of implantation, the secretion of the osteoprotegerin returns to the normal level, and the activation of the osteoclasts is beneficial to the normal processing of the bone remodeling process.

The disclosure relates to agents that inhibit the activity of osteoprotegerin and their use in the treatment of pulmonary hypertension.

In one aspect the present invention provides methods for promoting endothelial morphogenesis. The methods of this aspect of the invention include the step of providing to one or more endothelial cells an amount of an osteoprotegerin sufficient to promote endothelial morphogenesis. The methods of this aspect of the invention can be practiced in vivo or in vitro. In another aspect, the present invention provides implantable medical devices that each include: (a) a device body; and (b) a layer attached to a surface of the device body, the layer comprising a molecule selected from the group consisting of osteoprotegerin and a nucleic acid molecule encoding osteoprotegerin, wherein the device is adapted to be completely or partially implanted into an animal body. The implanted medical device thus promotes the growth of blood vessels in the surrounding tissue, thereby reducing or preventing the formation of a collagenous capsule around the implanted medical device.

The present invention relates to a molecular marker group for judging prognosis of aortic dissection. The molecular marker is a protein factor; the protein factor is TRAIL (TNF-related apoptosis inducing ligand), OPG (osteoprotegerin) and D-dimer. A judging method is characterized in that the score (LP) of one-year death risk is -5.2903+0.9318*Ln(OPG/TRAIL)+0.5227*Ln(D-dimer); the occurrence probability of one-year poor adverse effect (one-year risk of all-cause mortality) is 1-0.947^exp{LP}.

The invention discloses a recombinant lentiviral vector containing human osteoprotegerin gene as well as a preparation method and application thereof. The preparation method comprises the following steps: connecting a human osteoprotegerin gene coding sequence region on a T vector by means of cloning; connecting coding sequence fragments, containing Restriction enzyme cutting sites at two ends, of the human osteoprotegerin gene to a pIRES-EGFP vector by amplification, thereby obtaining an OPG-IRES-EGFP vector; amplifying an OPG-IRES-EGFP sequence, and subcloning to a vector pcDNA6.2w; and recombining the OPG-IRES-EGFP sequence on the pcDNA6.2w to an entry vector via BP, and further recombining to a pLenti6.3/V5 vector via LR, thereby obtaining Lenti6.3-hOPG-IRES-EGFP. The vector can realize sustained and stable expression of transfection gene in body, and can be used for stem cells and primary cells, which are very difficult to transfect.

Belonging to the technical field of research on the dose-effect of natural drug prescription compatibility and use, the invention discloses a natural drug composition for treatment of osteoporotic fracture and/or osteoarthritis and application thereof. The natural drug composition comprises, by mass percentage, 73.3%-98.3% of sea buckthorn fruit oil and 1.7%-26.7% of panax notoginseng saponins. The natural drug composition can transform and generate a signal molecule of eicosatrienoic acid, and the signal molecule can activate protein and cyclic nucleotide, calcium ion and other multi-path molecular signal pathways to generate the effect of synergistic amplification of signal molecule; the composition can improve the hematopoietic microenvironment, regulate endocrine, adjust the metabolic balance of osteoclast and osteoblast, reduce alkaline phosphatase, improve serum osteoprotegerin, osteocalcin and other bone metabolism marker indexes, increase the femur, tibia and vertebral bone density, significantly improves the bone remodeled bone shape and bone biomechanical symbolic indexes, and can effectively prevent and treat osteoporotic fracture, osteoarthritis and ostealgia diseases.

The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.

The invention relates to application of osteoprotegerin (OPG) only or combination of osteoprotegerin with other cytokines in treatment of hepatic fibrosis. Osteoprotegerin only or combination of osteoprotegerin with other cytokines can improve the condition of the hepatic fibrosis. Therefore, the hepatic fibrosis is better cured, or another feasible selection is provided for treating the hepatic fibrosis, and the prognosis or life quality of patients is improved.